feladilimab + chemotherapy

Feladilimab + chemotherapy is an investigational combination therapy composed of **feladilimab** (an anti-ICOS agonist monoclonal antibody) and conventional **chemotherapy** (most commonly platinum-based regimens with 5-fluorouracil). Feladilimab targets the **inducible T cell co-stimulatory receptor (ICOS)** on T cells and acts as an immunostimulant agonist, promoting T cell-mediated anti-tumor immune responses. The combination has been studied in advanced, solid tumors, particularly in **head and neck squamous cell carcinoma (HNSCC)** and other advanced malignancies, with the rationale of synergizing immune activation (from feladilimab) with cytotoxic antineoplastic effects from chemotherapy. Feladilimab was developed by GlaxoSmithKline; however, clinical development has been discontinued due to limited efficacy. The chemotherapy components were administered per standard of care protocols and may include agents such as 5-fluorouracil and platinum compounds[1][2][4][5].